These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 31384431)
1. Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension. Simpson CE; Damico RL; Hummers L; Khair RM; Kolb TM; Hassoun PM; Mathai SC Pulm Circ; 2019; 9(3):2045894019859477. PubMed ID: 31384431 [TBL] [Abstract][Full Text] [Related]
2. Association of Lymphangiogenic Factors With Pulmonary Arterial Hypertension in Systemic Sclerosis. Didriksen H; Molberg Ø; Fretheim H; Gude E; Jordan S; Brunborg C; Palchevskiy V; Garen T; Midtvedt Ø; Andreassen AK; Distler O; Belperio J; Hoffmann-Vold AM Arthritis Rheumatol; 2021 Jul; 73(7):1277-1287. PubMed ID: 33497027 [TBL] [Abstract][Full Text] [Related]
3. Serum uric acid is associated with disease severity and may predict clinical outcome in patients of pulmonary arterial hypertension secondary to connective tissue disease in Chinese: a single-center retrospective study. Wang J; Wang Y; Li X; Huang Y; Sun X; Wang Q; Zhang M BMC Pulm Med; 2020 Oct; 20(1):272. PubMed ID: 33076877 [TBL] [Abstract][Full Text] [Related]
5. Prevalence of Pulmonary Arterial Hypertension in Korean Adult Patients with Systemic Sclerosis: Result of a Pilot Echocardiographic Screening Study. Yoo SJ; Park JH; Park Y; Lee JH; Sun BJ; Kim J; Yoo IS; Shim SC; Kang SW J Cardiovasc Ultrasound; 2016 Dec; 24(4):312-316. PubMed ID: 28090259 [TBL] [Abstract][Full Text] [Related]
6. Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction. Bourji KI; Kelemen BW; Mathai SC; Damico RL; Kolb TM; Mercurio V; Cozzi F; Tedford RJ; Hassoun PM Pulm Circ; 2017; 7(2):409-420. PubMed ID: 28597765 [TBL] [Abstract][Full Text] [Related]
7. Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). Kolstad KD; Li S; Steen V; Chung L; Chest; 2018 Oct; 154(4):862-871. PubMed ID: 29777655 [TBL] [Abstract][Full Text] [Related]
8. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Williams MH; Handler CE; Akram R; Smith CJ; Das C; Smee J; Nair D; Denton CP; Black CM; Coghlan JG Eur Heart J; 2006 Jun; 27(12):1485-94. PubMed ID: 16682379 [TBL] [Abstract][Full Text] [Related]
9. Serum uric Acid as a prognostic predictor in pulmonary arterial hypertension with connective tissue disease. Njaman W; Iesaki T; Iwama Y; Takasaki Y; Daida H Int Heart J; 2007 Jul; 48(4):523-32. PubMed ID: 17827824 [TBL] [Abstract][Full Text] [Related]
10. Pulmonary arterial hypertension in Saudi patients with systemic sclerosis: Clinical and hemodynamic characteristics and mortality. Al Otair HA; Idrees MM; Saleemi SA; Eltoukhy AM; Alhijji AA; Al Habeeb WA; Omair MA Ann Thorac Med; 2019; 14(1):83-89. PubMed ID: 30745940 [TBL] [Abstract][Full Text] [Related]
11. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517 [TBL] [Abstract][Full Text] [Related]
12. Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. Dumitrescu D; Nagel C; Kovacs G; Bollmann T; Halank M; Winkler J; Hellmich M; Grünig E; Olschewski H; Ewert R; Rosenkranz S Heart; 2017 May; 103(10):774-782. PubMed ID: 28062514 [TBL] [Abstract][Full Text] [Related]
13. Evaluating the role of serum uric acid in the risk stratification and therapeutic response of patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD). Luo J; Li Y; Chen J; Qiu H; Chen W; Luo X; Chen Y; Tan Y; Li J Front Pharmacol; 2023; 14():1238581. PubMed ID: 37701027 [No Abstract] [Full Text] [Related]
16. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Humbert M; Yaici A; de Groote P; Montani D; Sitbon O; Launay D; Gressin V; Guillevin L; Clerson P; Simonneau G; Hachulla E Arthritis Rheum; 2011 Nov; 63(11):3522-30. PubMed ID: 21769843 [TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of mortality and 2-year survival analysis of systemic sclerosis with pulmonary arterial hypertension in Thailand. Foocharoen C; Nanagara R; Kiatchoosakun S; Suwannaroj S; Mahakkanukrauh A Int J Rheum Dis; 2011 Aug; 14(3):282-9. PubMed ID: 21816025 [TBL] [Abstract][Full Text] [Related]
18. Hemodynamic variables and clinical features correlated with serum uric acid in patients with pulmonary arterial hypertension. Jiang X; Han ZY; Wang Y; Xu XQ; Ma CR; Wu Y; Pan L; Jing ZC Chin Med J (Engl); 2008 Dec; 121(24):2497-503. PubMed ID: 19187585 [TBL] [Abstract][Full Text] [Related]
19. Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: a cohort study. Pasarikovski CR; Granton JT; Roos AM; Sadeghi S; Kron AT; Thenganatt J; Moric J; Chau C; Johnson SR Arthritis Res Ther; 2016 Jan; 18():30. PubMed ID: 26819137 [TBL] [Abstract][Full Text] [Related]